1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
  4. > Redbiotec AG - Product Pipeline Review - 2014

Redbiotec AG - Product Pipeline Review - 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 17 pages

Redbiotec AG - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Redbiotec AG - Product Pipeline Review - 2014’, provides an overview of the Redbiotec AG’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Redbiotec AG’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Redbiotec AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Redbiotec AG’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Redbiotec AG’s pipeline products

Reasons to buy

- Evaluate Redbiotec AG’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Redbiotec AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Redbiotec AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Redbiotec AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Redbiotec AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Redbiotec AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Redbiotec AG - Product Pipeline Review - 2014
Table of Contents
Redbiotec AG Snapshot 4
Redbiotec AG Overview 4
Key Information 4
Key Facts 4
Redbiotec AG - Research and Development Overview 5
Key Therapeutic Areas 5
Redbiotec AG - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Redbiotec AG - Drug Profiles 9
RBT-101 9
Product Description 9
Mechanism of Action 9
RandD Progress 9
RBT-201 10
Product Description 10
Mechanism of Action 10
RandD Progress 10
RBT-301 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
Redbiotec AG - Pipeline Analysis 12
Redbiotec AG - Pipeline Products by Molecule Type 12
Redbiotec AG - Recent Pipeline Updates 13
Redbiotec AG - Dormant Projects 14
Redbiotec AG - Locations And Subsidiaries 15
Head Office 15
Appendix 16
Methodology 16
Coverage 16
Secondary Research 16
Primary Research 16
Expert Panel Validation 16
Contact Us 17
Disclaimer 17

List of Tables

Redbiotec AG, Key Information 4
Redbiotec AG, Key Facts 4
Redbiotec AG - Pipeline by Indication, 2014 6
Redbiotec AG - Pipeline by Stage of Development, 2014 7
Redbiotec AG - Monotherapy Products in Pipeline, 2014 8
Redbiotec AG - Pipeline by Molecule Type, 2014 12
Redbiotec AG - Recent Pipeline Updates, 2014 13
Redbiotec AG - Dormant Developmental Projects,2014 14

List of Figures

Redbiotec AG - Pipeline by Top 10 Indication, 2014 6

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Circassia Pharmaceuticals Plc - Product Pipeline Review - 2016

Circassia Pharmaceuticals Plc - Product Pipeline Review - 2016

  • $ 1500
  • Company report
  • August 2016
  • by Global Markets Direct

Circassia Pharmaceuticals Plc - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘Circassia Pharmaceuticals Plc - Product Pipeline Review - 2016’, provides an overview of the Circassia ...

iBio, Inc. - Product Pipeline Review - 2016

iBio, Inc. - Product Pipeline Review - 2016

  • $ 1500
  • Company report
  • August 2016
  • by Global Markets Direct

iBio, Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘iBio, Inc. - Product Pipeline Review - 2016’, provides an overview of the iBio, Inc.’s pharmaceutical research and ...

Theravectys SA - Product Pipeline Review - 2016

Theravectys SA - Product Pipeline Review - 2016

  • $ 1500
  • Company report
  • October 2016
  • by Global Markets Direct

Theravectys SA - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘Theravectys SA - Product Pipeline Review - 2016’, provides an overview of the Theravectys SA’s pharmaceutical research ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.